diclofenac has been researched along with Hematochezia in 50 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
Hematochezia: The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multi-centre, double-blind, randomised parallel-group study was conducted to compare the efficacy and safety between etodolac SR and diclofenac in treating patients with osteoarthritis of the knee." | 9.10 | Double-blind, randomised, comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee. ( Hsu, PN; Liang, TH, 2003) |
| "A prespecified pooled intent-to-treat analysis of three double-blind randomised comparisons of etoricoxib (60 or 90 mg daily) and diclofenac (150 mg daily) in 34 701 patients with osteoarthritis or rheumatoid arthritis was done for upper gastrointestinal clinical events (bleeding, perforation, obstruction, or ulcer) and the subset of complicated events (perforation, obstruction, witnessed ulcer bleeding, or significant bleeding)." | 8.84 | Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L, 2007) |
| "To identify the unbiased differences in the risk of hospitalization with peptic ulcer disease (PUD) or gastrointestinal (GI) hemorrhage among populations using 4 nonsteroidal antiinflammatory drugs (NSAID): nabumetone, Arthrotec, diclofenac plus a cytoprotective agent dispensed separately (diclo+coRx), and naproxen." | 7.73 | Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study. ( Ashworth, NL; Muhajarine, N; Peloso, PM; Stang, M, 2005) |
| " Evaluation of the profile of adverse events was the main aim of the trial, together with assessment of efficacy." | 6.69 | Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. ( Alegre, C; Baumelou, E; Bégaud, B; Dequeker, J; Hawkey, C; Isomäki, H; Kahan, A; Littlejohn, G; Mau, J; Papazoglou, S; Steinbrück, K, 1998) |
| "Patients >or=50 years old with osteoarthritis or rheumatoid arthritis were randomly assigned to etoricoxib (60 or 90 mg qd) or diclofenac (150 mg qd)." | 5.13 | Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. ( Cannon, CP; Cryer, B; Curtis, SP; Jensen, DM; Kaur, A; Laine, L; Langman, M, 2008) |
| "A multi-centre, double-blind, randomised parallel-group study was conducted to compare the efficacy and safety between etodolac SR and diclofenac in treating patients with osteoarthritis of the knee." | 5.10 | Double-blind, randomised, comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee. ( Hsu, PN; Liang, TH, 2003) |
| "Twenty-three patients, mean age 69 years, with osteoarthritis requiring NSAID treatment, received treatment with diclofenac 100 mg/day, naproxen 750 mg/day and piroxicam 20 mg/day, representing a short, medium and long half-life NSAID respectively, in a double-blind, randomised, three way, cross-over block design." | 5.08 | NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant? ( Christophidis, N; Kwiatek, R; Scharf, S; Ugoni, A, 1998) |
| "A prespecified pooled intent-to-treat analysis of three double-blind randomised comparisons of etoricoxib (60 or 90 mg daily) and diclofenac (150 mg daily) in 34 701 patients with osteoarthritis or rheumatoid arthritis was done for upper gastrointestinal clinical events (bleeding, perforation, obstruction, or ulcer) and the subset of complicated events (perforation, obstruction, witnessed ulcer bleeding, or significant bleeding)." | 4.84 | Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L, 2007) |
| " In randomised, controlled clinical trials, lumiracoxib 100 - 200 mg/day has been shown to be superior to placebo in patients with symptomatic osteoarthritis, with clinical efficacy similar to diclofenac 150 mg/day, celecoxib 200 mg/day or rofecoxib 25 mg/day." | 4.82 | Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor. ( Bannwarth, B; Berenbaum, F, 2005) |
| "Prespecified analysis of all 8 double-blind, randomized phase 2b/3 rofecoxib osteoarthritis trials conducted from December 1996 through March 1998, including one 6-week dose-ranging study, two 6-week efficacy studies vs ibuprofen and placebo, two 1-year efficacy studies vs diclofenac, two 6-month endoscopy studies vs ibuprofen and placebo, and one 6-week efficacy study vs nabumetone and placebo." | 4.80 | Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. ( Bolognese, JA; Harper, SE; Jensen, DM; Langman, MJ; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 1999) |
| "To identify the unbiased differences in the risk of hospitalization with peptic ulcer disease (PUD) or gastrointestinal (GI) hemorrhage among populations using 4 nonsteroidal antiinflammatory drugs (NSAID): nabumetone, Arthrotec, diclofenac plus a cytoprotective agent dispensed separately (diclo+coRx), and naproxen." | 3.73 | Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study. ( Ashworth, NL; Muhajarine, N; Peloso, PM; Stang, M, 2005) |
| "The risk of a newly diagnosed episode of upper gastrointestinal bleeding, acute liver and renal failure, agranulocytosis, aplastic anemia, severe skin disorders, and anaphylaxis was examined within 30 days after the first prescription for a low dose of diclofenac, naproxen, or ibuprofen in a cohort in the United Kingdom." | 3.70 | Low-dose diclofenac, naproxen, and ibuprofen cohort study. ( Duque-Oliart, A; García-Rodríguez, LA; Pérez-Gutthann, S; Varas-Lorenzo, C, 1999) |
| "Repeat oral dosing of nabumetone for 1 month maintains anti-inflammatory efficacy in a carrageenan model of paw oedema yet does not cause gastrointestinal damage." | 3.68 | Anti-inflammatory efficacy and gastrointestinal irritancy: comparative 1 month repeat oral dose studies in the rat with nabumetone, ibuprofen and diclofenac. ( Blower, PR; Gentry, C; Melarange, R; O'Connell, C, 1991) |
| " Evaluation of the profile of adverse events was the main aim of the trial, together with assessment of efficacy." | 2.69 | Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. ( Alegre, C; Baumelou, E; Bégaud, B; Dequeker, J; Hawkey, C; Isomäki, H; Kahan, A; Littlejohn, G; Mau, J; Papazoglou, S; Steinbrück, K, 1998) |
| " Traditional NSAIDs are associated with an increased risk of serious gastrointestinal (GI) adverse events versus COX-2 selective inhibitors, and chronic use frequently necessitates adjunctive therapy with gastroprotective agents." | 2.44 | Efficacy of the newest COX-2 selective inhibitors in rheumatic disease. ( Baraf, HS, 2007) |
| "We report on 3 cases in which ano-rectal lesions were associated with chronic administration of suppositories containing non-steroidal anti-inflammatory drugs (NSAID)." | 1.28 | Ano-rectal lesions in patients taking suppositories containing non-steroidal anti-inflammatory drugs (NSAID). ( Biasco, G; Brandi, G; Di Febo, G; Gizzi, G; Paganelli, GM; Villani, V, 1990) |
| "Diclofenac (Voltarol) has no effect on carbohydrate metabolism, insulin levels or tolbutamide metabolism, nor does it enhance the effect of tolbutamide, biguanide or glibenclamide." | 1.26 | Diclofenac sodium (Voltarol): drug interactions and special studies. ( Fowler, PD, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (16.00) | 18.7374 |
| 1990's | 12 (24.00) | 18.2507 |
| 2000's | 19 (38.00) | 29.6817 |
| 2010's | 10 (20.00) | 24.3611 |
| 2020's | 1 (2.00) | 2.80 |
| Authors | Studies |
|---|---|
| Van Vertloo, LR | 1 |
| Terhaar, HM | 1 |
| Viall, AK | 1 |
| Allbaugh, RA | 1 |
| Singh, DP | 1 |
| Borse, SP | 1 |
| Rana, R | 1 |
| Nivsarkar, M | 1 |
| Kinsey, SG | 2 |
| Cole, EC | 1 |
| Kratt, T | 1 |
| Lange, J | 1 |
| Königsrainer, A | 1 |
| Malek, N | 1 |
| Adam, P | 1 |
| Bösmüller, H | 1 |
| Goetz, M | 1 |
| Lee, J | 1 |
| Burke, DT | 1 |
| Kang, WH | 1 |
| Nguyen, HV | 1 |
| Park, C | 1 |
| Choi, YW | 1 |
| Lee, BJ | 1 |
| Laine, L | 2 |
| Curtis, SP | 2 |
| Langman, M | 1 |
| Jensen, DM | 2 |
| Cryer, B | 2 |
| Kaur, A | 2 |
| Cannon, CP | 2 |
| Aftab, AR | 1 |
| Donnellan, F | 1 |
| Zeb, F | 1 |
| Kevans, D | 1 |
| Cullen, G | 1 |
| Courtney, G | 1 |
| Rahme, E | 1 |
| Bernatsky, S | 1 |
| Morini, S | 1 |
| Zullo, A | 1 |
| Altman, RD | 1 |
| Nomura, DK | 1 |
| O'Neal, ST | 1 |
| Long, JZ | 1 |
| Mahadevan, A | 1 |
| Cravatt, BF | 1 |
| Grider, JR | 1 |
| Lichtman, AH | 1 |
| Mamdani, M | 1 |
| Rochon, PA | 1 |
| Juurlink, DN | 1 |
| Kopp, A | 1 |
| Anderson, GM | 1 |
| Naglie, G | 1 |
| Austin, PC | 1 |
| Laupacis, A | 1 |
| Li, RW | 1 |
| Zhang, YH | 1 |
| Ji, H | 1 |
| Yu, XL | 1 |
| Peng, SX | 1 |
| Mahajan, SK | 1 |
| Vaidya, P | 1 |
| Sood, BR | 1 |
| Gupta, D | 1 |
| Sharma, A | 1 |
| Lanas, A | 1 |
| Liang, TH | 1 |
| Hsu, PN | 1 |
| Oviedo, JA | 1 |
| Wolfe, MM | 1 |
| Shi, W | 1 |
| Wang, YM | 1 |
| Li, SL | 1 |
| Yan, M | 1 |
| Li, D | 1 |
| Chen, BY | 1 |
| Cheng, NN | 1 |
| Dial, EJ | 1 |
| Dohrman, AJ | 1 |
| Romero, JJ | 1 |
| Lichtenberger, LM | 1 |
| Bannwarth, B | 1 |
| Berenbaum, F | 1 |
| McCarthy, DM | 1 |
| Ashworth, NL | 1 |
| Peloso, PM | 1 |
| Muhajarine, N | 1 |
| Stang, M | 1 |
| Psaty, BM | 1 |
| Weiss, NS | 1 |
| Parashar, A | 1 |
| Baraf, HS | 1 |
| Uthgenannt, H | 3 |
| Letzel, H | 1 |
| Arent, H | 1 |
| Kaufman, DW | 1 |
| Kelly, JP | 1 |
| Sheehan, JE | 1 |
| Laszlo, A | 1 |
| Wiholm, BE | 1 |
| Alfredsson, L | 1 |
| Koff, RS | 1 |
| Shapiro, S | 1 |
| O'Hanlon, JJ | 1 |
| Beers, H | 1 |
| Huss, BK | 1 |
| Milligan, KR | 1 |
| Newman, L | 1 |
| Scharf, S | 1 |
| Kwiatek, R | 1 |
| Ugoni, A | 1 |
| Christophidis, N | 1 |
| Hawkey, C | 1 |
| Kahan, A | 1 |
| Steinbrück, K | 1 |
| Alegre, C | 1 |
| Baumelou, E | 1 |
| Bégaud, B | 1 |
| Dequeker, J | 1 |
| Isomäki, H | 1 |
| Littlejohn, G | 1 |
| Mau, J | 1 |
| Papazoglou, S | 1 |
| Pérez-Gutthann, S | 1 |
| García-Rodríguez, LA | 1 |
| Duque-Oliart, A | 1 |
| Varas-Lorenzo, C | 1 |
| Langman, MJ | 1 |
| Watson, DJ | 1 |
| Harper, SE | 1 |
| Zhao, PL | 1 |
| Quan, H | 1 |
| Bolognese, JA | 1 |
| Simon, TJ | 1 |
| Jick, SS | 1 |
| Muthu, A | 1 |
| Qureshi, A | 1 |
| Ismail, MA | 1 |
| Wildgrube, HJ | 1 |
| Kierschke, G | 1 |
| Nowak, H | 1 |
| Weigmann, I | 1 |
| Terhaag, B | 1 |
| Pemberton, RE | 1 |
| Strand, LJ | 1 |
| Osnes, M | 1 |
| Larsen, S | 1 |
| Eidsaunet, W | 1 |
| Thom, E | 1 |
| Fowler, PD | 1 |
| Beró, T | 1 |
| Nagy, L | 1 |
| Jávor, T | 1 |
| Vincze, A | 1 |
| Melarange, R | 1 |
| Gentry, C | 1 |
| O'Connell, C | 1 |
| Blower, PR | 1 |
| Gizzi, G | 1 |
| Villani, V | 1 |
| Brandi, G | 1 |
| Paganelli, GM | 1 |
| Di Febo, G | 1 |
| Biasco, G | 1 |
| Carson, J | 1 |
| Notis, WM | 1 |
| Orris, ES | 1 |
| Rimbau, V | 1 |
| Fernandez, MF | 1 |
| Guirao, I | 1 |
| Torralba, A | 1 |
| Izquierdo, E | 1 |
| Bown, RL | 1 |
| Martin, BK | 1 |
| Geddawi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis[NCT00092703] | Phase 3 | 6,000 participants | Interventional | 2002-06-27 | Completed | ||
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis[NCT00092742] | Phase 3 | 4,086 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis[NCT00250445] | Phase 3 | 23,498 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| A 12-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Ibuprofen 2400 mg in Patients With Osteoarthritis (Study 1)[NCT00269191] | Phase 3 | 528 participants (Actual) | Interventional | 2003-02-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for diclofenac and Hematochezia
13 trials available for diclofenac and Hematochezia
| Article | Year |
|---|---|
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
Double-blind, randomised, comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee.
Topics: Abdominal Pain; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase | 2003 |
Gastrointestinal blood loss in volunteers following fenclofenac and diclofenac.
Topics: Anti-Inflammatory Agents; Diclofenac; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Phenyl | 1981 |
[Effect of 3-(4-chlorphenyl-) 1-phenyl-1H-pyrazole-4-acetic acid (lonazolac-Ca), diclofenac-Na and indomethacin on the gastrointestinal blood loss].
Topics: Anti-Inflammatory Agents; Diclofenac; Digestive System; Gastrointestinal Hemorrhage; Humans; Indomet | 1982 |
Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Dic | 1993 |
A comparison of the effect of intramuscular diclofenac, ketorolac or piroxicam on post-operative pain following laparoscopy.
Topics: Adult; Analgesia; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Bronchial Disea | 1996 |
NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant?
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over S | 1998 |
Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind M | 1998 |
[Application of quantifying scoring systems for the determination of changes in the mucosa of the upper gastrointestinal tract. A comparative study of a diclofenac effervescent tablet with conventional diclofenac preparations and acetylsalicylic acid afte
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diclofenac; Drug Combinations; Endoscopy; F | 2002 |
[Gastrointestinal discharge of blood due to the administration of feprazon, naproxen, diclofenac].
Topics: Diclofenac; Feprazone; Gastrointestinal Hemorrhage; Humans; Melena; Naphthaleneacetic Acids; Naproxe | 1977 |
A review of upper-gastrointestinal effects of the newer nonsteroidal antiinflammatory agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Clinical Trials as | 1979 |
Effect of diclofenac and naproxen on gastroduodenal mucosa.
Topics: Adult; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Duodenum; Female; Gastric Mucosa; | 1979 |
Comparison of occult blood loss caused by pirazolac and diclofenac sodium: a double-blind crossover study.
Topics: Adult; Anti-Inflammatory Agents; Chromium Radioisotopes; Diclofenac; Double-Blind Method; Erythrocyt | 1985 |
31 other studies available for diclofenac and Hematochezia
| Article | Year |
|---|---|
Retrospective evaluation of the incidence of gastrointestinal bleeding in dogs receiving ophthalmic nonsteroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dog Diseases; Dogs; Flurbiprofen; Gast | 2023 |
Curcumin, a component of turmeric, efficiently prevents diclofenac sodium-induced gastroenteropathic damage in rats: A step towards translational medicine.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Curcuma; Curcumin; Diclofenac; Gastrointestinal He | 2017 |
Acute Δ(9)-tetrahydrocannabinol blocks gastric hemorrhages induced by the nonsteroidal anti-inflammatory drug diclofenac sodium in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Catalepsy; Diclofenac; Dronabino | 2013 |
Successful Hemospray treatment for recurrent diclofenac-induced severe diffuse lower gastrointestinal bleeding avoiding the need for colectomy.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Colonic Diseases; Colonoscopy; Diclofenac; Female; Ga | 2014 |
Lower gastrointestinal bleeding associated with diclofenac topical patch in a patient with colonic mass and on antiplatelet therapy for atrial fibrillation.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Atrial Fibrillation; Clopidogrel; Colonic Neoplasms; | 2014 |
Modulation of microenvironmental pH for dual release and reduced in vivo gastrointestinal bleeding of aceclofenac using hydroxypropyl methylcellulose-based bilayered matrix tablet.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations; Diclofenac; Dogs; Dru | 2017 |
NSAID-induced colopathy. A case series.
Topics: Aged; Anemia, Iron-Deficiency; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colon; Colonic Disea | 2010 |
NSAIDs and risk of lower gastrointestinal bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Coloni | 2010 |
[Does dual antiplatelet therapy always require gastroprotection? Gastroprotection with proton pump inhibitors is advisable for all patients who need dual antiplatelet therapy].
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cyclo | 2010 |
Safety advantages of topical versus oral nonsteroidal antiinflammatory drugs.
Topics: Administration, Oral; Administration, Topical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclof | 2011 |
Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice.
Topics: Amidohydrolases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzodioxoles; Cannabinoid Recept | 2011 |
Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2; Diclofen | 2002 |
[Synthesis and anti-inflammatory analgesic activities of phenylfuroxan-coupled diclofenac].
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclic N-Oxides; Diclofenac; Digestive | 2002 |
Duodenal diverticular haemorrhage in a patient taking NSAID.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Diverticulum; Duodenal Diseases; Fluoroscopy; G | 2003 |
Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygen | 2003 |
[Pain therapy in rheumatism. After 65 years of age coxibs are the best choice].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Cyclooxygenase Inhibitors; Dicl | 2003 |
Risk factors of adverse drug reaction from non-steroidal anti-inflammatory drugs in Shanghai patients with arthropathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheu | 2004 |
Recombinant human lactoferrin prevents NSAID-induced intestinal bleeding in rodents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Gastrointestinal Hemorrhage; Humans; I | 2005 |
Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cohort Studies; Databas | 2005 |
NSAID trials and the choice of comparators--questions of public health importance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials, Phase IV as Topic | 2007 |
Gastrointestinal safety of NSAIDs versus COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Gastroin | 2007 |
Upper gastrointestinal bleeding following major maxillofacial surgery.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Carcinoma, Squamous Cell; Chemopre | 1997 |
Low-dose diclofenac, naproxen, and ibuprofen cohort study.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Anaphylaxis; Anti-Inflammatory Agen | 1999 |
The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cyclooxygenase 2; Cyclooxygenase 2 In | 2000 |
Massive bleeding from colonic diverticular disease with NSAID use.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Diclofenac; Diverticulum, Colon; Gastrointestina | 1999 |
Diclofenac sodium (Voltarol): drug interactions and special studies.
Topics: Adult; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Blood Coagulation Factors; Blood Glucose; | 1979 |
Measurement of non-steroid antiinflammatory drugs induced gastric microbleeding.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Apazone; Diclofenac; Gastric Juice; Gastrointestinal | 1992 |
Anti-inflammatory efficacy and gastrointestinal irritancy: comparative 1 month repeat oral dose studies in the rat with nabumetone, ibuprofen and diclofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Butanones; Carrageenan; Diclofenac; E | 1991 |
Ano-rectal lesions in patients taking suppositories containing non-steroidal anti-inflammatory drugs (NSAID).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anus Diseases; Diclofenac; Endoscopy; Female; Gastro | 1990 |
Colonic ulceration and bleeding during diclofenac therapy.
Topics: Aged; Colonic Diseases; Diclofenac; Female; Gastrointestinal Hemorrhage; Humans; Middle Aged; Tablet | 1990 |
Comparative study of the gastrointestinal tolerance of diclofenac and aceclofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Gastrointestinal Diseases; Gastrointes | 1988 |